Lundbeck A/S
Lundbeck A/S
-0.76 %
381.20 DKK
-2.90
Quote
381.20
High
389.00
Change
-0.76 %
Low
380.60
Updated
21/09/2018
Open
385.50
News about Lundbeck A/S
Factsheet for Lundbeck A/S
Company Profile
Description
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs worldwide, including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, and Onfi for epilepsy.
Key Stats
Website: http://www.lundbeck.com
Headquarter country: Denmark
Employees: 5,379
Market Cap (at close 21/09/2018): DKK 76B
Fiscal Year Ends: December
Stats

Stats 2017 2016 2015 2014 2013
Price/Earnings 24.40 198.10 51.90 48.00 27.50
Forward Price/Earnings 16.20 48.10 69.00 43.70 31.40
Price/Free Cash Flow 19.40 23.30 420.10 40.20 14.30
Return on Assets 13.10 5.80 -24.20 -0.600 3.80
Return on Equity 24.00 13.10 -51.00 -1.10 6.40
Return on Invested Capital 22.70 10.70 -37.70 -1.60 6.00
Dividend


Dividend/Share:2.40
Ex. Dividend Date:31/12/2017
Trailing Dividend Yield:2.08
Payout Ratio:43.74
Date Currency Amount
31/03/2018 DKK 8.00
31/03/2017 DKK 2.45
31/03/2014 DKK 2.77
31/03/2013 DKK 2.00
Income Statement

Revenue 2017 2016 2015 2014 2013
Total Revenue 17,234 15,634 14,594 13,468 15,258
Gross Profit 13.35 11.55 9.20 9.31 11.22
Gross Margin % 77.48% 73.89% 63.03% 69.11% 73.54%
Operating Expenses 2017 2016 2015 2014 2013
EBITDA 4,591.00 4,018.00 498.00 409.00 1,753.00
Net income 2,624.00 1,211.00 -5,694.00 -153.00 855.00
Basic Earnings Per Share 13.28 6.14 -28.98 -0.780 4.36
Operating Income 4.17 2.29 -6.82 0.100 1.60
Operating Margin % 24.17% 14.66% -46.70% 0.740% 10.48%
Cash Flow

Cash Flow 2017 2016 2015 2014 2013
Operating Cash Flow 4,045.00 3,126.00 197.00 1,610.00 3,760.00
Capital Expenditures -725.00 -342.00 -2,956.00 -1,549.00 -1,515.00
Free Cash Flow 3,320.00 2,784.00 -2,759.00 61.00 2,245.00
Balance Sheet

Assets 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Current Assets 8,844,000 7,524,000 7,660,000 9,386,000 11,363,000
Long Term Assets 10,912,000 12,686,000 13,665,000 16,251,000 12,286,000
Total Assets 19,756,000 20,210,000 21,325,000 25,637,000 23,649,000
Liabilities 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Total Current Liabilities 6,479,000 7,776,000 7,748,000 7,202,000 6,518,000
Long Term Liabilities 1,096,000 2,740,000 4,792,000
Total Liabilities 7,575,000 10,516,000 12,540,000
Equity 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Retained Earnings 10,170,000 7,772,000 6,296,000 11,898,000 12,694,000
Treasury Stock
Total Stockholder Equity 12,181,000 9,694,000 8,785,000 13,526,000 13,481,000
Net Tangible Assets 4,616,000 855,000 -1,009,000 856,000 4,404,000